Last reviewed · How we verify
A arm (DA-90)
DA-90 is a monoclonal antibody targeting CD19.
DA-90 is a monoclonal antibody targeting CD19. Used for Relapsed or refractory B-cell acute lymphoblastic leukemia.
At a glance
| Generic name | A arm (DA-90) |
|---|---|
| Also known as | Daunorubicin, Cytarabine |
| Sponsor | Polish Adult Leukemia Group |
| Drug class | CD19-targeting monoclonal antibody |
| Target | CD19 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
DA-90 works by binding to CD19 on the surface of B cells, marking them for destruction by the immune system. This leads to the depletion of cancerous B cells in the body.
Approved indications
- Relapsed or refractory B-cell acute lymphoblastic leukemia
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |